Suvorexant for insomnia in patients with psychiatric disorder: A 1‐week, open‐label study
Abstract Aim There have been no previous reports on the efficacy and safety of suvorexant for insomnia in people with psychiatric disorders. Methods This one‐week, prospective, single‐arm, clinical trial of fixed dose of suvorexant (20 mg if ages 18–64 or 15 mg if age ≥ 65 years) for insomnia includ...
| Үндсэн зохиолчид: | , , , , , , , , , , |
|---|---|
| Формат: | Өгүүллэг |
| Хэл сонгох: | English |
| Хэвлэсэн: |
Wiley
2019-09-01
|
| Цуврал: | Neuropsychopharmacology Reports |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://doi.org/10.1002/npr2.12069 |